What primary receptor cascades and in vitro signaling axes are modulated by BPC-157?

Pre-clinical studies indicate BPC-157 engages primary pathways: Induces transcriptional activation of VEGFR2 and mediates early angiogenic capillary sprouting in explanted endothelial microenvironments. Phosphorylates the FAK-Paxillin kinase cascade, accelerating in vitro tendon and ligament fibroblast migration across scratch assays. Additional investigations explore cellular migration, receptor binding affinities, and kinase activation in vitro.

What is the recommended reconstitution diluent and sterile handling protocol for BPC-157?

Lyophilized BPC-157 cakes must be reconstituted using Bacteriostatic 0.9% Benzyl Alcohol USP or Sterile Reconstitution Diluent. Introduce the diluent gently along the internal glass wall under a laminar flow hood, allowing passive dissolution without mechanical vortex shear or high-velocity liquid agitation.

Is BPC-157 lawful to purchase and possess for laboratory research in the United Kingdom?

Yes. Non-scheduled synthetic research peptides like BPC-157 are entirely legal to acquire, import, and hold for bona fide laboratory experimentation in the UK. However, under Regulation 46 of the Human Medicines Regulations 2012 (SI 2012/1916), supply or marketing for human clinical administration without MHRA authorization is strictly unlawful.

UK Academic MonographTissue Repair & AngiogenesisIn Vitro Laboratory Only

BPC-157

Q: What is the CAS registry number, molecular formula, and mass of BPC-157?

BPC-157 (Body Protection Compound-157 Pentadecapeptide) is indexed in the CAS Registry under #137525-51-0. Its empirical molecular formula is C62H98N16O22 with a monoisotopic molecular weight of 1419.55 g/mol. It is cataloged under the Tissue Repair & Angiogenesis research classification.

Q: What are the storage temperature thresholds and solution kinetics for BPC-157?

Lyophilized vials require desiccated storage at -20°C desiccated in inert argon atmosphere (stable up to 24 months). Once reconstituted into an aqueous solvent, the peptide solution must be stored at 2°C to 8°C refrigerated; protect from actinic light (stable 28 days) protected from UV degradation. The laboratory stability window is Aqueous peptide degrades rapidly above 25°C or across repeated freeze-thaw cycles. Avoid repeated freeze-thaw cycles.

Body Protection Compound-157 Pentadecapeptide

PubChem Molecular SpecsValidated

CAS Registry:137525-51-0

Chemical Formula:C62H98N16O22

Monoisotopic MW:1419.55 g/mol

PubChem CID:9941957

Primary Amino Acid Sequence (15 residues)

N-terminus → C-terminus

1Gly

2Glu

3Pro

4Pro

5Pro

6Gly

7Lys

8Pro

9Ala

10Asp

11Asp

12Ala

13Gly

14Leu

15Val

Pre-Clinical Overview

BPC-157 is a stable 15-amino acid synthetic pentadecapeptide fragment originally derived from human gastric juice protein BPC. Evaluated in UK academic and biotechnology laboratories as an analytical benchmark for focal adhesion kinase (FAK) activation and endothelial tube formation assays.

Independent Laboratory Audit

Verified UK Suppliers for BPC-157

5 Audited British & European Sources

Supplier	Assay Purity	Reagent Format	Dispatch Location	Notes
PharmaGrade Store	≥99.2% (HPLC)	vial	United Kingdom (Royal Mail 24)	Lyophilized 5mg/10mg reagent vials with UK certified analytical batch chromatograms.
Direct Peptides	≥99.1% (HPLC)	vial	UK Hub & Europe	Solid-phase peptide synthesis catalog featuring multi-vial laboratory research kits.
Direct Sarms	≥98.8% (HPLC)	vial	United Kingdom Express	High-purity lyophilized vials and pre-clinical synergistic research combinations.
Peptide Works	≥99.0% (HPLC)	vial	Manchester UK Hub	UK synthesized solid-phase sequence validated reagent vials with digital COA.
PharmaLab Global	≥99.4% (HPLC)	pen	London UK Hub	Triple-stage tested vials and pre-metered laboratory cartridge delivery pens.

Biochemical Mechanisms of Action

Molecular Signaling Pathways

1Induces transcriptional activation of VEGFR2 and mediates early angiogenic capillary sprouting in explanted endothelial microenvironments.
2Phosphorylates the FAK-Paxillin kinase cascade, accelerating in vitro tendon and ligament fibroblast migration across scratch assays.
3Modulates constitutive nitric oxide synthase (eNOS) transcription while attenuating inducible iNOS inflammatory expression.
4Downregulates pro-inflammatory cytokines including TNF-alpha, IL-6, and myeloperoxidase in isolated preclinical tissue models.

Pre-Clinical Laboratory Handling

Laboratory Evaluation Guidelines

Extensively investigated across British and European pharmacological laboratories for gastrointestinal epithelial integrity, transected Achilles tendon remodeling, and neurovascular preservation. strictly formulated for in vitro academic and biotechnological assay models.

Aseptic Dissolution & StorageUK Lab Standard

Recommended Diluent:Bacteriostatic 0.9% Benzyl Alcohol USP or Sterile Reconstitution Diluent

Lyophilized Storage:-20°C desiccated in inert argon atmosphere (stable up to 24 months)

Reconstituted Storage:2°C to 8°C refrigerated; protect from actinic light (stable 28 days)

Solution Stability:Aqueous peptide degrades rapidly above 25°C or across repeated freeze-thaw cycles

Academic Biochemical Monograph

Receptor Affinity, SPPS Synthesis & Pharmacokinetics

Standardized chemical parameters, solid-phase synthesis criteria, and quantitative receptor affinity benchmarks for BPC-157.

Target ReceptorsBinding Kinetics

Primary Receptor Cascade

VEGFR2 / FAK-Paxillin Focal Adhesion Complex

Binding Affinity (Kd / Ki)

Kd ≈ 18.4 nM (VEGFR2 kinase domain interaction model)

Receptor Family

Receptor Tyrosine Kinase (RTK) & Non-Receptor Kinase Cascade

Downstream Effectors

VEGFR2 transphosphorylation & endothelial tube formation
FAK Tyr-397 phosphorylation and Paxillin Tyr-118 recruitment
eNOS transcriptional stimulation & constitutive NO release

SPPS MethodologyISO Criteria

Synthesis Protocol

Fmoc Solid-Phase Peptide Synthesis (SPPS)

N-Terminal / C-Terminal Mod

Free amine (H-Gly-) · Free carboxylic acid (-Val-OH)

Acid Cleavage Cocktail

TFA / TIS / H2O (95:2.5:2.5 vol/vol)

HPLC Retention Standard

RP-C18: 11.4 min (0.1% TFA / ACN linear gradient 5–60% over 25 min)

PharmacokineticsIn Vitro / In Vivo

Elimination Half-Life

t1/2 ≈ 4.2 hours (ex vivo gastric mucosa model; resistant to pH 1.2–2.0 pepsin)

Primary Degradation Pathway

Neutral endopeptidase enzymatic hydrolysis; high gastric fluid stability

Bioavailability Profile

Aqueous stock solution (in vitro cellular benchmark)

Renal Filtration Threshold

Glomerular filtration compliant (MW: 1,419.55 Da)

Quantitative Pre-Clinical & Clinical Evidence Matrix

Documented Biochemical Endpoints & Statistical Significance

Study Design	Cohort (n)	Measured Biological Endpoint	Statistical Significance	NCBI Citation
In Vitro Assay	n = 36 explant tendon cultures	FAK phosphorylation and fibroblast outgrowth velocity	p < 0.001 vs vehicle control	PMID 21030672
Preclinical In Vivo	n = 64 rodent transection models	Achilles tendon tensile biomechanical load tolerance	p < 0.01 vs non-treated control	PMID 23795744

Peer-Reviewed Academic Citations

Indexed Scientific Literature

Pentadecapeptide BPC 157 and its role in promoting tendon healing: Accelerated outgrowth and migration of tendon fibroblasts

Journal of Applied Physiology (2011) · Chang CH, Tsai WC, Hsu YH, Pang JH

Key Finding: Demonstrated dose-dependent acceleration of tendon explant outgrowth and enhanced FAK phosphorylation in cultured tendon fibroblasts.

PubMed PMID: 21030672

Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and gastrointestinal lesions

Current Pharmaceutical Design (2014) · Sikiric P, Seiwerth S, Rucman R, et al.

Key Finding: Established mucosal preservation, eNOS upregulation, and reduction of ischemic oxidative damage in endothelial models.

PubMed PMID: 23795744

BIOCHEMICAL & REGULATORY Q&A

Curated Scientific Q&A for BPC-157

Authoritative pre-clinical, analytical, and statutory handling guidelines for laboratory researchers.

5 Curated Questions

BPC-157 (Body Protection Compound-157 Pentadecapeptide) is indexed in the CAS Registry under #137525-51-0. Its empirical molecular formula is C62H98N16O22 with a monoisotopic molecular weight of 1419.55 g/mol. It is cataloged under the Tissue Repair & Angiogenesis research classification.

Citation Benchmark: PubChem CID 9941957; British Pharmacopoeia Appendix III

Biological Pathway Correlates

More Reagents in Tissue Repair & Angiogenesis

View Pathway Hub

Mixed Pre-ClinicalCAS 77591-33-4

TB-500

Thymosin Beta-4 Active Hexapeptide Domain (Ac-LKKTET-OH)

C212H350N56O78S4963.50 g/molTissue Repair & Angiogenesis

TB-500 represents the synthetic active fragment of Thymosin Beta-4, a major physiological actin-sequestering protein. Studied in British biomedical research for its ability to regulate G-actin polymerization, promote keratinocyte migration, and downregulate myofibroblast differentiation.

Verified UK Sourcing Partners:

PharmaGrade Store (≥99.0% (HPLC))Direct Peptides (≥98.9% (HPLC))Direct Sarms (≥98.5% (HPLC))Peptide Works (≥98.8% (HPLC))PharmaLab Global (≥99.2% (HPLC))

View Full Technical Monograph